These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 36959692)

  • 1. Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center.
    Cengiz Seval G; Civriz Bozdag S; Toprak SK; Kurt Yuksel M; Topcuoglu P; Arslan O; Demirer T; Gurman G; Beksac M; Ilhan O; Ozcan M
    Balkan Med J; 2023 May; 40(3):197-204. PubMed ID: 36959692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Allogeneic Stem Cell Transplant in the Treatment of Primary Myelofibrosis.
    Soyer N; Celik F; Tombuloglu M; Sahin F; Saydam G; Vural F
    Exp Clin Transplant; 2019 Feb; 17(1):93-96. PubMed ID: 27855592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.
    Keyzner A; Han S; Shapiro S; Moshier E; Schorr E; Petersen B; Najfeld V; Kremyanskaya M; Isola L; Hoffman R; Mascarenhas J
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2180-2186. PubMed ID: 27596130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
    Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
    Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation.
    Konuma T; Kanda J; Uchida N; Nishijima A; Tanaka M; Ozawa Y; Sawa M; Onizuka M; Ota S; Maruyama Y; Kanda Y; Kawakita T; Ara T; Eto T; Nakamae H; Kimura T; Fukuda T; Atsuta Y;
    Hematol Oncol; 2023 Feb; 41(1):147-158. PubMed ID: 36268564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
    Chhabra S; Narra RK; Wu R; Szabo A; George G; Michaelis LC; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Pasquini MC; Rizzo RD; Saber W; Shah NN; Shaw BE; Hamadani M; Hari PN
    Biol Blood Marrow Transplant; 2020 May; 26(5):893-901. PubMed ID: 31982543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
    Bewersdorf JP; Sheth AH; Vetsa S; Grimshaw A; Giri S; Podoltsev NA; Gowda L; Tamari R; Tallman MS; Rampal RK; Zeidan AM; Stahl M
    Transplant Cell Ther; 2021 Oct; 27(10):873.e1-873.e13. PubMed ID: 34052505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
    Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry.
    Lwin Y; Kennedy G; Gottlieb D; Kwan J; Ritchie D; Szer J; Milliken S; Browett P; Spencer A; Butler A; Bardy P; Greenwood M; Perera T; He S; McEwan A; Larsen S; Lai H; Purtill D; Tran S; Aarons D; Hamad N
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2252-2261. PubMed ID: 32861814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
    García-Cadenas I; Redondo S; Esquirol A; Portos JM; Novelli S; Saavedra S; Moreno C; Garrido A; Oñate G; López J; Caballero AC; Miqueleiz S; Arguello-Tomas M; Briones J; Sierra J; Martino R
    Transplant Cell Ther; 2023 Jul; 29(7):473.e1-473.e6. PubMed ID: 37086849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
    Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.